Arbutus Biopharma Corporation

ABUS

CA03879J1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
4.260 ^USD	-1.39%		-5.96%	-11.43%

Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT

Top Midday Decliners

Published on 01/16/2026 at 01:37 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Arbutus Biopharma Corporation

Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT
Mar. 04	US Equity Markets End Higher After Strong Services, Jobs Data	MT
Mar. 04	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
Mar. 04	Wall Street mixed as oil retreat eases inflation fears
Mar. 04	Top Midday Stories: Bessent Says US to Fortify Gulf Oil Trade, 15% Tariff Rolling Out This Week; CrowdStrike Fiscal Q4 Adjusted Earnings, Revenue Increase	MT
Mar. 04	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
Mar. 04	Moderna to pay $950m to end litigation
Mar. 04	Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang	RE
Mar. 03	Moderna Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
Mar. 03	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute	RE
Mar. 03	Roivant announces Genevant Sciences' and Arbutus Biopharma's $2.25 billion global settlement with Moderna	RE
Mar. 03	Genevant Sciences and Arbutus Biopharma announce $2.25 billion global settlement with Moderna	RE
Feb. 18	Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma	MT
Jan. 16	Top Midday Decliners	MT

Chart Arbutus Biopharma Corporation

Duration

Period

ABUS: Dynamic Chart

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ€™ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Employees

Sector

Biotechnology & Medical Research

More about the company